INT164582

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2006
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 56
Total Number 60
Disease Relevance 67.11
Pain Relevance 2.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (MCL1) nucleoplasm (MCL1) mitochondrion (MCL1)
nucleus (MCL1) cytoplasm (MCL1)
Anatomy Link Frequency
colon 1
superior 1
MCL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 48 99.98 Very High Very High Very High
cINOD 10 98.44 Very High Very High Very High
COX-2 inhibitor 12 98.00 Very High Very High Very High
Inflammation 36 86.84 High High
antagonist 3 85.76 High High
dexamethasone 3 84.08 Quite High
imagery 21 73.28 Quite High
ischemia 14 67.84 Quite High
metalloproteinase 14 66.96 Quite High
agonist 43 50.00 Quite Low
Disease Link Frequency Relevance Heat
Apoptosis 5109 100.00 Very High Very High Very High
Obesity 578 100.00 Very High Very High Very High
Repression 7 100.00 Very High Very High Very High
Carcinoma 4325 99.92 Very High Very High Very High
Colon Cancer 141 99.60 Very High Very High Very High
Sarcoma 92 99.60 Very High Very High Very High
Death 363 99.54 Very High Very High Very High
Heart Rate Under Development 256 99.52 Very High Very High Very High
Skin Cancer 94 99.36 Very High Very High Very High
Squamous Cell Carcinoma 10 99.22 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Additionally, Mcl-1 downregulation sensitized cells towards chemotherapy combined with MEK1, Raf I kinase, mTOR, VEFG/PDGF receptor tyrosine kinase, or EGF receptor tyrosine kinase inhibition (Fig. 5A, and data not shown).
Negative_regulation (downregulation) of Mcl-1
1) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.61 Pain Relevance 0
However, in a concentration of 50 ng/ml, TRAIL-induced apoptosis was slightly enhanced by downregulation of Mcl-1 (Fig. 5A, p < 0.05).


Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
2) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.02 Pain Relevance 0
Mcl-1 downregulation might improve therapeutic regimens targeting VEGF or PDGF signaling in HCC.
Negative_regulation (downregulation) of Mcl-1 associated with carcinoma
3) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.21 Pain Relevance 0
Downregulation of Mcl-1 significantly enhanced apoptosis induced by PI3K inhibition.
Negative_regulation (Downregulation) of Mcl-1 associated with apoptosis
4) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.22 Pain Relevance 0
Mcl-1 downregulation by siRNA alone did not induce apoptosis (Fig. 3B).
Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
5) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.44 Pain Relevance 0
Again, Mcl-1 downregulation only sligthly sensitized Huh7 cells to this combinatorial approach (significant difference for 50 ng/ml).
Negative_regulation (downregulation) of Mcl-1
6) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.14 Pain Relevance 0
However, after specific downregulation of Mcl-1 by RNA interference, apoptosis was induced (17.2% after 24 h, p < 0.001) (Fig. 4).
Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
7) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.79 Pain Relevance 0
Mcl-1 downregulation, however, when combined with MEK1 inhibition and chemotherapy, triggered apoptosis in Huh7 cells.
Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
8) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.03 Pain Relevance 0
Sensitizing HCC cells towards combined treatment modalities after downregulation of Mcl-1
Negative_regulation (downregulation) of Mcl-1 associated with carcinoma
9) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.01 Pain Relevance 0
In contrast to the results of the current study, Mcl-1 downregulation by ASO treatment in HCC cell lines resulted in spontaneous apoptosis without an additional apoptotic stimulus [28].
Negative_regulation (downregulation) of Mcl-1 associated with carcinoma and apoptosis
10) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.96 Pain Relevance 0
Furthermore, downregulation of Mcl-1 did not sensitize Huh7 cells towards UV irradiation-induced apoptosis (7.5 and 15 mJ/cm2, 24 h; Fig. 3B).
Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
11) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.94 Pain Relevance 0
Thus, we also tested the activity of caspase-3 and -9 after chemotherapy with or without downregulation of Mcl-1.
Negative_regulation (downregulation) of Mcl-1
12) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.91 Pain Relevance 0
In the current study, MEK1 inhibition by PD98059 with or without downregulation of Mcl-1 did not induce significant apoptosis rates in Huh7 cells.
Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
13) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.03 Pain Relevance 0
However, Mcl-1 downregulation sensitized Huh7 cells towards a panel of chemotherapeutic drugs including epirubicin, mitomycin C, and 5-FU (Fig. 3B).
Negative_regulation (downregulation) of Mcl-1
14) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.38 Pain Relevance 0
Again, apoptosis rates were not higher than after treatment with Mcl-1 downregulation and chemotherapy alone.
Negative_regulation (downregulation) of Mcl-1 associated with apoptosis
15) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.09 Pain Relevance 0
Our data also add to studies on other tumor types such as malignant melanoma and sarcoma, in which specific downregulation of Mcl-1 has been shown to sensitize cancer cells to chemotherapeutic drug-induced apoptosis [25,26].
Negative_regulation (downregulation) of Mcl-1 associated with sarcoma, cancer, apoptosis and skin cancer
16) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.80 Pain Relevance 0
No sensitization by Mcl-1 downregulation was observed in cells treated with 5-FU/VA and the JNK1-inhibitor SP600125 or the Src kinase inhibitor PP2, respectively (data not shown).
Negative_regulation (downregulation) of Mcl-1
17) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.46 Pain Relevance 0
In the current study, EGFR tyrosine kinase inhibition alone did not result in HCC cell death even if combined with Mcl-1 downregulation.
Negative_regulation (downregulation) of Mcl-1 associated with carcinoma and death
18) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.14 Pain Relevance 0
In addition, no sensitization was observed by downregulation of Mcl-1 (Fig. 4).
Negative_regulation (downregulation) of Mcl-1
19) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.07 Pain Relevance 0
The molecular mechanisms that mediate the pro-apoptotic effect of Mcl-1 downregulation in HCC cells remain elusive and are subject to further studies.
Negative_regulation (downregulation) of Mcl-1 associated with carcinoma and apoptosis
20) Confidence 0.56 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.92 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox